Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Tekmira Rides A Big Day In RNAi

It was only the day after Christmas when I mentioned that Tekmira (TKMR) was a name that investors should think about investigating as a potentially cheaper play on RNA interference (RNAi) than better-known representatives of the class like Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (ISIS). The stock had done pretty well since then (up about 20% in two weeks), but news of a deal with Monsanto (NYSE:MON) gave another boost to the shares.

Now I'm starting to wonder if things are getting a little too crazy in RNAi-land. Alnylam was up very strongly on news of its partnership with Sanofi (NYSE:SNY) and Tekmira too was up more than one-third in the peak...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details